A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...

Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, ...

Riluzole treatment and a diet containing high glycemic index foods interact 'synergistically' to slow ALS progression, ...

Seeding activity of human superoxide dismutase 1 aggregates in familial and sporadic amyotrophic lateral sclerosis postmortem neural tissues by real-time quaking-induced conversion (Acta ...

Dozens of people in one North Carolina family all have amyotrophic lateral sclerosis, a deadly disease with no cure that is ...

(ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's ...

Seeding activity of human superoxide dismutase 1 aggregates in familial and sporadic amyotrophic lateral sclerosis postmortem neural tissues by real-time quaking-induced conversion (Acta ...

Introduction: T regulatory cells (Tregs) inversely correlate with disease progression in Amyotrophic Lateral Sclerosis (ALS) and fast-progressing ALS patients have been reported to exhibit ...

Early signs and symptoms of multiple sclerosis (MS) can vary for each person. MS onset symptoms can include vision issues, weakness, tingling, numbness, and more. MS is a relapsing or progressive ...